These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16490770)

  • 1. A high-throughput cell-based assay for inhibitors of ABCG2 activity.
    Henrich CJ; Bokesch HR; Dean M; Bates SE; Robey RW; Goncharova EI; Wilson JA; McMahon JB
    J Biomol Screen; 2006 Mar; 11(2):176-83. PubMed ID: 16490770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
    Sim HM; Lee CY; Ee PL; Go ML
    Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New inhibitors of ABCG2 identified by high-throughput screening.
    Henrich CJ; Robey RW; Bokesch HR; Bates SE; Shukla S; Ambudkar SV; Dean M; McMahon JB
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3271-8. PubMed ID: 18089721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
    Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
    Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
    Hofman J; Ahmadimoghaddam D; Hahnova L; Pavek P; Ceckova M; Staud F
    Pharmacol Res; 2012 Mar; 65(3):312-9. PubMed ID: 22173067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pheophorbide a is a specific probe for ABCG2 function and inhibition.
    Robey RW; Steadman K; Polgar O; Morisaki K; Blayney M; Mistry P; Bates SE
    Cancer Res; 2004 Feb; 64(4):1242-6. PubMed ID: 14973080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
    Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
    Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Biochemistry; 2006 Jul; 45(29):8940-51. PubMed ID: 16846237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
    Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
    Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.